Study ML41591, is an umbrella trial that will evaluate the efficacy and safety of various therapies in patients with Stage IB, IIA, IIB, IIIA, selected IIIB (only T3N2) (8th edition AJCC TNM staging) resectable and untreated NSCLC tumors that meet protocol specified biomarker criteria determined in a Clinical Laboratory Improvement Amendments (CLIA) certified laboratory.
This trial will evaluate the efficacy and safety of various therapies in patients with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated non-small cell lung cancer (NSCLC) tumors that meet protocol-specified biomarker criteria.
Are 18 years of age or older, have a diagnosis of Early Stage Non-Small Cell Lung Cancer, have a specific molecular alteration which will be determined by lab tests, will have surgery to remove the cancer, have adequate Lung and Heart Function Additional requirements will be discussed with your doctor and/or study representative. Click the NCT number link below to learn more about this study on ClinicalTrials.gov.
Principal Investigator